(PRWEB UK) 19 November 2014
Leading human models of disease research company Retroscreen Virology has announced one of its leadership team will be speaking at 2014 Respiratory Syncytial Virus Symposium in South Africa.
Dr Robert Lambkin-Williams, Executive Scientific Advisor at Retroscreen Virology, is going to be talking about the Retroscreen hVIVO model, how it can be applied to help accelerate drug and vaccine development, and the transfer of data from Human Challenge studies to field studies.
The 9th Respiratory Syncytial Virus Symposium (“RSV 2014”), which takes place between 9-13th November 2014 in Stellenbosch, is the official conference of the RSV scientific community. The event welcomes a number of key industry speakers as well as an exhibition of pharmaceutical and medical equipment products. Retroscreen, who will be sponsoring an industry session on Tuesday 11th November between 18:00 – 20:00, specialise in the provision of clinical services to third party study sponsors, helping to accelerate drug development.
Established in 1988, the business was set up to commercialise the academic research of Professor John Oxford in the field of retroviruses. Early studies conducted at Retroscreen were led by Dr. Robert Lambkin-Williams and Dr. Anthony Gilbert, who were tasked with developing a series of well-characterised virus stocks whilst showing clients that the Human Viral Challenge Model is a cost effective and efficient means of testing their therapeutics and taking them to market. Since its inception, Retroscreen has successfully carried out over 40 clinical studies, involving more than 85 quarantines and in excess of 1800 volunteers for a cross-section of leading industry, governmental and academic clients.
Dr Lambkin-Williams said: “I’m looking forward to attending this well respected annual event. I am passionate about the Human Viral Challenge Model and am delighted to have the opportunity to speak during the industry session sponsored by Retroscreen in the evening of 11th November. And we are really proud to have a select group of very eminent scientific colleagues also providing insight into their use of the hVIVO challenge model to help accelerate drug development.”
About Retroscreen Virology
Established in 1988, Retroscreen Virology Group PLC is a leading life sciences company in the UK. The team at Retroscreen has carried out studies in influenza, the common cold (HRV) and Respiratory Syncytial Virus (RSV) and is now developing the hVIVO model to expand out into studies using patient volunteers who already have an existing condition, such as asthma or COPD. Retroscreen Virology is committed to creating the next generation of drugs and vaccines for respiratory diseases.